|
BE792533A
(fr)
|
1971-12-09 |
1973-06-08 |
Int Chem & Nuclear Corp |
Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
|
|
JPS5868521A
(ja)
|
1981-10-16 |
1983-04-23 |
Hitachi Ltd |
流体継手の羽根車
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US5994514A
(en)
|
1991-08-14 |
1999-11-30 |
Genentech, Inc. |
Immunoglobulin variants
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
JPH07291996A
(ja)
|
1994-03-01 |
1995-11-07 |
Yuu Honshiyo |
ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
|
|
JP2778921B2
(ja)
|
1994-11-18 |
1998-07-23 |
三共株式会社 |
イミダゾピラゾール誘導体
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
JP5004390B2
(ja)
|
1999-08-23 |
2012-08-22 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
新規ｂ７−４分子およびその用途
|
|
PL354286A1
(en)
|
1999-08-23 |
2003-12-29 |
Dana-Farber Cancer Institutedana-Farber Cancer Institute |
Pd-1, a receptor for b7-4, and uses therefor
|
|
JP2003508401A
(ja)
|
1999-08-27 |
2003-03-04 |
アボット・ラボラトリーズ |
Ｃｏｘ−２阻害薬として有用なスルホニルフェニルピラゾール化合物
|
|
JP2003509428A
(ja)
|
1999-09-17 |
2003-03-11 |
アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー |
治療薬としてのピラゾロピリミジン
|
|
US20040038339A1
(en)
|
2000-03-24 |
2004-02-26 |
Peter Kufer |
Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
|
|
JP2003531149A
(ja)
|
2000-04-13 |
2003-10-21 |
ザ・ロツクフエラー・ユニバーシテイ |
抗体由来の免疫応答の増強
|
|
US20020094989A1
(en)
|
2000-10-11 |
2002-07-18 |
Hale Jeffrey J. |
Pyrrolidine modulators of CCR5 chemokine receptor activity
|
|
ATE540579T1
(de)
|
2000-11-15 |
2012-01-15 |
Ono Pharmaceutical Co |
Pd-1-defiziente maus und ihre verwendung
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
WO2002050071A1
(en)
|
2000-12-21 |
2002-06-27 |
Bristol-Myers Squibb Company |
Thiazolyl inhibitors of tec family tyrosine kinases
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
RU2003129528A
(ru)
|
2001-03-07 |
2005-04-10 |
Мерк Патент ГмбХ (DE) |
Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
|
|
AP2002002460A0
(en)
|
2001-03-09 |
2002-06-30 |
Pfizer Prod Inc |
Novel benzimidazole anti-inflammatory compounds.
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
WO2003004497A1
(en)
|
2001-07-05 |
2003-01-16 |
Sumitomo Pharmaceuticals Company, Limited |
Novel heterocyclic compound
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
CN1771231B
(zh)
|
2002-08-26 |
2011-05-25 |
武田药品工业株式会社 |
钙受体调节性化合物及其用途
|
|
EP1572113B1
(en)
|
2002-08-26 |
2017-05-17 |
Takeda Pharmaceutical Company Limited |
Calcium receptor modulating compound and use thereof
|
|
WO2004042017A2
(en)
|
2002-10-31 |
2004-05-21 |
Genentech, Inc. |
Methods and compositions for increasing antibody production
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US7405295B2
(en)
|
2003-06-04 |
2008-07-29 |
Cgi Pharmaceuticals, Inc. |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
|
US20060183746A1
(en)
|
2003-06-04 |
2006-08-17 |
Currie Kevin S |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
|
WO2005005429A1
(en)
|
2003-06-30 |
2005-01-20 |
Cellular Genomics, Inc. |
Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
|
|
WO2005011597A2
(en)
|
2003-07-29 |
2005-02-10 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
WO2005047290A2
(en)
|
2003-11-11 |
2005-05-26 |
Cellular Genomics Inc. |
Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
GB0400440D0
(en)
|
2004-01-09 |
2004-02-11 |
Isis Innovation |
Receptor modulators
|
|
EP1810979B1
(en)
|
2004-09-22 |
2012-06-20 |
Kyowa Hakko Kirin Co., Ltd. |
STABILIZED HUMAN IgG4 ANTIBODIES
|
|
AU2005304473A1
(en)
|
2004-11-10 |
2006-05-18 |
Cgi Pharmaceuticals, Inc. |
Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
|
|
US7767687B2
(en)
|
2004-12-13 |
2010-08-03 |
Biogen Idec Ma Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
|
|
US8101770B2
(en)
|
2004-12-16 |
2012-01-24 |
Vertex Pharmaceuticals Incorporated |
Pyridones useful as inhibitors of kinases
|
|
TW200639163A
(en)
|
2005-02-04 |
2006-11-16 |
Genentech Inc |
RAF inhibitor compounds and methods
|
|
MX2007011041A
(es)
|
2005-03-10 |
2008-02-22 |
Cgi Pharmaceuticals Inc |
Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
CA2611861C
(en)
|
2005-06-08 |
2017-11-28 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for the treatment of persistent infections
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
ATE548363T1
(de)
|
2005-08-29 |
2012-03-15 |
Vertex Pharma |
3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
|
|
EP1919906B1
(en)
|
2005-08-29 |
2011-10-12 |
Vertex Pharmaceuticals Incorporated |
3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
|
|
WO2007026720A1
(ja)
|
2005-08-31 |
2007-03-08 |
Taisho Pharmaceutical Co., Ltd. |
縮環ピラゾール誘導体
|
|
WO2007026950A1
(en)
|
2005-09-01 |
2007-03-08 |
Astellas Pharma Inc. |
Pyridazinone derivatives used for the treatment of pain
|
|
WO2007067444A1
(en)
|
2005-12-08 |
2007-06-14 |
Millennium Pharmaceuticals, Inc. |
Bicyclic compounds with kinase inhibitory activity
|
|
KR20080098490A
(ko)
|
2006-01-13 |
2008-11-10 |
파마시클릭스, 인코포레이티드 |
티로신 키나제 억제제 및 이의 용도
|
|
RU2429244C2
(ru)
|
2006-03-23 |
2011-09-20 |
Байоарктик Ньюросайенс Аб |
Улучшенные селективные в отношении протофибрилл антитела и их применение
|
|
EP2021327B1
(en)
|
2006-05-15 |
2012-04-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
WO2007136790A2
(en)
|
2006-05-18 |
2007-11-29 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
諾華公司 |
吡咯并嘧啶化合物及其用途
|
|
CN101104640A
(zh)
|
2006-07-10 |
2008-01-16 |
苏州大学 |
抗人pd-l1单克隆抗体制备及应用
|
|
CN101528729A
(zh)
|
2006-08-23 |
2009-09-09 |
辉瑞产品公司 |
作为gsk-3抑制剂的嘧啶酮化合物
|
|
EP2061761A1
(en)
|
2006-09-07 |
2009-05-27 |
Millennium Pharmaceuticals, Inc. |
Phenethylamide derivatives with kinase inhibitory activity
|
|
AR063946A1
(es)
|
2006-09-11 |
2009-03-04 |
Cgi Pharmaceuticals Inc |
Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
|
|
PE20081370A1
(es)
|
2006-09-11 |
2008-11-28 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
|
|
AR063706A1
(es)
|
2006-09-11 |
2009-02-11 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
|
|
WO2008033858A2
(en)
|
2006-09-11 |
2008-03-20 |
Cgi Pharmaceuticals, Inc. |
Kinase inhibitors, and methods of using and identifying kinase inhibitors
|
|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
|
JP2010505859A
(ja)
|
2006-10-06 |
2010-02-25 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
タンパク質キナーゼ阻害剤およびそれを使用するための方法
|
|
CA2668286C
(en)
|
2006-11-03 |
2014-09-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
CN101730699A
(zh)
|
2007-03-21 |
2010-06-09 |
百时美施贵宝公司 |
可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
|
|
KR20090130345A
(ko)
|
2007-05-04 |
2009-12-22 |
아이알엠 엘엘씨 |
Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 화합물 및 조성물
|
|
WO2008144253A1
(en)
|
2007-05-14 |
2008-11-27 |
Irm Llc |
Protein kinase inhibitors and methods for using thereof
|
|
JP6071165B2
(ja)
|
2007-05-31 |
2017-02-01 |
ゲンマブ エー／エス |
安定なＩｇＧ４抗体
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
WO2009024531A1
(en)
|
2007-08-17 |
2009-02-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating and diagnosing hematologic malignancies
|
|
CL2008002793A1
(es)
|
2007-09-20 |
2009-09-04 |
Cgi Pharmaceuticals Inc |
Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
TWI552752B
(zh)
|
2007-10-19 |
2016-10-11 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
CN101835755B
(zh)
|
2007-10-23 |
2013-12-11 |
霍夫曼-拉罗奇有限公司 |
激酶抑制剂
|
|
JP5643105B2
(ja)
|
2007-12-14 |
2014-12-17 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体
|
|
PL2242749T3
(pl)
|
2008-02-05 |
2013-09-30 |
Hoffmann La Roche |
Nowe pirydynony i pirydazynony
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
CA2723237A1
(en)
|
2008-05-06 |
2009-11-12 |
Peter A. Blomgren |
Substituted amides, method of making, and use as btk inhibitors
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
NZ603525A
(en)
|
2008-06-27 |
2015-02-27 |
Celgene Avilomics Res Inc |
Pyrimidine based compound and uses thereof
|
|
PE20110164A1
(es)
|
2008-07-02 |
2011-03-28 |
Hoffmann La Roche |
Nuevas fenilpirazinonas como inhibidores de quinasa
|
|
WO2010006947A1
(en)
|
2008-07-15 |
2010-01-21 |
F. Hoffmann-La Roche Ag |
Novel phenyl-imidazopyridines and pyridazines
|
|
CA2730930C
(en)
|
2008-07-16 |
2015-01-13 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
|
ES2461494T3
(es)
|
2008-07-18 |
2014-05-20 |
F. Hoffmann-La Roche Ag |
Nuevas fenilimidazopirazinas
|
|
US8476430B2
(en)
|
2008-07-24 |
2013-07-02 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
JP2012501654A
(ja)
|
2008-09-05 |
2012-01-26 |
アビラ セラピューティクス， インコーポレイテッド |
不可逆的インヒビターの設計のためのアルゴリズム
|
|
US9181342B2
(en)
|
2008-09-12 |
2015-11-10 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
EP2348860B1
(en)
|
2008-10-31 |
2015-05-27 |
Genentech, Inc. |
Pyrazolopyrimidine jak inhibitor compounds and methods
|
|
US20120028981A1
(en)
|
2008-11-05 |
2012-02-02 |
Principia Biopharma Inc. |
Kinase Knockdown Via Electrophilically Enhanced Inhibitors
|
|
US8598174B2
(en)
|
2008-11-12 |
2013-12-03 |
Genetech, Inc. |
Pyridazinones, method of making, and method of use thereof
|
|
MX2011005691A
(es)
|
2008-11-28 |
2011-07-20 |
Univ Emory |
Metodos para el tratamiento de infecciones y tumores.
|
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
WO2010068810A2
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Certain substituted amides, method of making, and method of use thereof
|
|
WO2010068788A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Heterocyclic amides as btk inhibitors
|
|
WO2010068806A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
|
|
US8084620B2
(en)
|
2008-12-19 |
2011-12-27 |
Bristol-Myers Squibb Company |
Carbazole carboxamide compounds useful as kinase inhibitors
|
|
US20100197924A1
(en)
|
2008-12-22 |
2010-08-05 |
Millennium Pharmaceuticals, Inc. |
Preparation of aminotetralin compounds
|
|
EP3828185B1
(en)
|
2009-01-06 |
2024-11-20 |
Dana-Farber Cancer Institute, Inc. |
Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
|
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
US8299077B2
(en)
|
2009-03-02 |
2012-10-30 |
Roche Palo Alto Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
WO2010122038A1
(en)
|
2009-04-24 |
2010-10-28 |
F. Hoffmann-La Roche Ag |
Inhibitors of bruton's tyrosine kinase
|
|
US8765754B2
(en)
|
2009-04-29 |
2014-07-01 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
|
EP2440204B1
(en)
|
2009-06-12 |
2013-12-18 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
US8846673B2
(en)
|
2009-08-11 |
2014-09-30 |
Bristol-Myers Squibb Company |
Azaindazoles as kinase inhibitors and use thereof
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
NZ598985A
(en)
|
2009-09-04 |
2013-07-26 |
Biogen Idec Inc |
Bruton's tyrosine kinase inhibitors
|
|
EP2485589A4
(en)
|
2009-09-04 |
2013-02-06 |
Biogen Idec Inc |
HETEROARYL-BTK INHIBITORS
|
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
ES2617281T3
(es)
|
2009-10-28 |
2017-06-16 |
Janssen Biotech, Inc. |
Anticuerpos anti-glp-1r y sus usos
|
|
US10053513B2
(en)
|
2009-11-30 |
2018-08-21 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
HUE030100T2
(en)
|
2010-02-19 |
2017-04-28 |
Xencor Inc |
New CTLA4-IG immunoadhesins
|
|
JP2013528357A
(ja)
|
2010-03-29 |
2013-07-11 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
EP2566869B1
(en)
|
2010-05-07 |
2016-03-02 |
Gilead Connecticut, Inc. |
Pyridone and aza-pyridone compounds and methods of use
|
|
TWI500617B
(zh)
|
2010-05-31 |
2015-09-21 |
Ono Pharmaceutical Co |
Purine ketone derivatives
|
|
CA3007787C
(en)
|
2010-06-03 |
2020-03-10 |
Pharmacyclics Llc |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
|
WO2011159857A1
(en)
|
2010-06-16 |
2011-12-22 |
Bristol-Myers Squibb Company |
Carboline carboxamide compounds useful as kinase inhibitors
|
|
MX342164B
(es)
|
2010-06-23 |
2016-09-19 |
Hanmi Science Co Ltd |
Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
|
|
US20120053189A1
(en)
|
2010-06-28 |
2012-03-01 |
Pharmacyclics, Inc. |
Btk inhibitors for the treatment of immune mediated conditions
|
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
MX336875B
(es)
|
2010-08-10 |
2016-02-04 |
Celgene Avilomics Res Inc |
Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
|
|
AR082590A1
(es)
|
2010-08-12 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores de la tirosina-quinasa de bruton
|
|
US8975260B2
(en)
|
2010-09-01 |
2015-03-10 |
Genetech, Inc |
Pyridazinones, method of making, and method of use thereof
|
|
CA2809836C
(en)
|
2010-09-01 |
2019-01-15 |
Gilead Connecticut, Inc. |
Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
|
|
US9505826B2
(en)
|
2010-12-22 |
2016-11-29 |
Teva Pharmaceuticals Australia Pty Ltd |
Modified antibody with improved half-life
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
PT2691112T
(pt)
|
2011-03-31 |
2018-07-10 |
Merck Sharp & Dohme |
Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
|
|
JP6147727B2
(ja)
|
2011-04-01 |
2017-06-14 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
|
|
CA2760174A1
(en)
|
2011-12-01 |
2013-06-01 |
Pharmascience Inc. |
Protein kinase inhibitors and uses thereof
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
CN103596958A
(zh)
|
2011-04-20 |
2014-02-19 |
葛兰素集团有限公司 |
用作抗结核病化合物的四氢吡唑并[1,5-a]嘧啶
|
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
PL2710005T3
(pl)
|
2011-05-17 |
2017-07-31 |
Principia Biopharma Inc. |
Inhibitory kinazy tyrozynowej
|
|
AU2012257802A1
(en)
|
2011-05-17 |
2013-10-31 |
F. Hoffmann-La Roche Ag |
Inhibitors of Bruton's tyrosine kinase
|
|
US20140107151A1
(en)
|
2011-05-17 |
2014-04-17 |
Principia Biophama Inc. |
Tyrosine kinase inhibitors
|
|
DK3424953T3
(en)
|
2011-06-06 |
2020-11-02 |
Novo Nordisk As |
Terapeutiske antistoffer
|
|
MX354412B
(es)
|
2011-06-10 |
2018-03-05 |
Merck Patent Gmbh |
Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
|
|
ES2677367T3
(es)
|
2011-06-22 |
2018-08-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anticuerpos anti-Axl y usos de los mismos
|
|
ES2548414T3
(es)
|
2011-07-08 |
2015-10-16 |
Novartis Ag |
Novedosos derivados de pirrolo pirimidina
|
|
MX368257B
(es)
|
2011-08-01 |
2019-09-26 |
Genentech Inc |
Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
PL2797888T3
(pl)
|
2011-12-31 |
2016-12-30 |
|
Połączone związki tricykliczne jako inhibitory kinazy raf
|
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
|
US10011660B2
(en)
|
2012-04-30 |
2018-07-03 |
Medimmune, Llc |
Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
JP2015526409A
(ja)
|
2012-07-03 |
2015-09-10 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
Ｃ−末端及び中心エピトープａ−ベータ抗体
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
EP2934577A1
(en)
|
2012-12-19 |
2015-10-28 |
Adimab, LLC |
Multivalent antibody analogs, and methods of their preparation and use
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
MY178882A
(en)
|
2013-02-20 |
2020-10-21 |
Regeneron Pharma |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
EP2968454B1
(en)
|
2013-03-15 |
2019-02-13 |
Regeneron Pharmaceuticals, Inc. |
Il-33 antagonists and uses thereof
|
|
CA2902686C
(en)
|
2013-04-25 |
2017-01-24 |
Beigene, Ltd. |
Fused heterocyclic compounds as protein kinase inhibitors
|
|
WO2014194302A2
(en)
|
2013-05-31 |
2014-12-04 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
ES2822665T3
(es)
*
|
2013-05-31 |
2021-05-04 |
Merck Sharp & Dohme |
Terapias de combinación para el cáncer
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
EA201690746A1
(ru)
|
2013-10-25 |
2016-12-30 |
Фармасайкликс Элэлси |
Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
CN106687446B
(zh)
|
2014-07-18 |
2020-04-28 |
百济神州(北京)生物科技有限公司 |
作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
|
|
TW201618775A
(zh)
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物
|
|
US10035802B2
(en)
|
2014-08-14 |
2018-07-31 |
Teva Pharmaceuticals Usa, Inc. |
Solid state forms of ibrutinib
|
|
TW201625304A
(zh)
|
2014-10-24 |
2016-07-16 |
美國禮來大藥廠 |
泌尿上皮癌之療法
|
|
WO2016087994A1
(en)
|
2014-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
|
|
SG11201704808VA
(en)
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
US20180193274A1
(en)
|
2014-12-24 |
2018-07-12 |
Principia Biopharma Inc. |
Compositions for ileo-jejunal drug delivery
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
CN113307805A
(zh)
|
2015-04-15 |
2021-08-27 |
百济神州有限公司 |
B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途
|
|
ES2789500T5
(es)
|
2015-05-29 |
2023-09-20 |
Hoffmann La Roche |
Procedimientos terapéuticos y de diagnóstico para el cáncer
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
US20190054090A1
(en)
|
2015-10-01 |
2019-02-21 |
Gilead Sciences, Inc. |
Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
|
|
WO2017165491A1
(en)
*
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
|
|
US10864203B2
(en)
|
2016-07-05 |
2020-12-15 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
|
WO2018033853A2
(en)
|
2016-08-16 |
2018-02-22 |
Beigene, Ltd. |
Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
WO2018033135A1
(en)
|
2016-08-19 |
2018-02-22 |
Beigene, Ltd. |
Use of a combination comprising a btk inhibitor for treating cancers
|
|
US11203637B2
(en)
|
2016-08-26 |
2021-12-21 |
Beigene, Ltd. |
Anti-Tim-3 antibodies and use thereof
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CN110087730B
(zh)
|
2016-09-27 |
2023-03-28 |
百济神州(苏州)生物科技有限公司 |
使用包含parp抑制剂的组合产品治疗癌症
|
|
MY203000A
(en)
|
2016-10-14 |
2024-06-01 |
Xencor Inc |
Il15/il15r� heterodimeric fc-fusion proteins
|
|
US11555038B2
(en)
|
2017-01-25 |
2023-01-17 |
Beigene, Ltd. |
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
EP3612839A1
(en)
|
2017-04-20 |
2020-02-26 |
ADC Therapeutics SA |
Combination therapy
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
US11377449B2
(en)
|
2017-08-12 |
2022-07-05 |
Beigene, Ltd. |
BTK inhibitors with improved dual selectivity
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
US20210040213A1
(en)
|
2018-02-09 |
2021-02-11 |
Beigene, Ltd. |
Immunomonotherapy for urothelial carcinoma
|
|
GB201803746D0
(en)
|
2018-03-08 |
2018-04-25 |
Ultrahuman Eight Ltd |
PD1 binding agents
|